Market Overview

Guillain-Barre Syndrome | A Pipeline Analysis Report 2018 | Technavio

Share:

Technavio has announced their latest pipeline analysis report on the Guillain-Barre
syndrome market
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat the Guillain-Barre syndrome.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180723005534/en/

Technavio has published a new report on the drug development pipeline for Guillain-Barre syndrome, i ...

Technavio has published a new report on the drug development pipeline for Guillain-Barre syndrome, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Guillain-Barre syndrome: Market overview

Guillain-Barre syndrome (GBS) is an autoimmune disorder in which the
immune system mistakenly attacks healthy nerve cells, thus leading to
weakness in the muscles, numbness, and tingling. It can eventually cause
paralysis. The immune system destroys the myelin sheath surrounding the
axons of peripheral nerves, which carry nerve signals. Nerve cells start
losing the ability to transmit signals efficiently when myelin sheath is
injured. The actual cause of GBS is unknown, but it usually occurs a few
days after a patient had symptoms of a respiratory or gastrointestinal
viral infection. Zika virus infection is also linked to GBS.

According to a senior market research analyst at Technavio, "According
to the Centers for Disease Control and Prevention report in August 2016,
GBS is associated with Zika and in many countries where the population
is affected with Zika, have reported an increase in GBS patient
population. CDC also stated that every year, approximately 3,000-6,000
people in the US develop GBS. With the increase in the age, the
incidences of GBS also increases. As a result, with the rising
incidences of the disease, the requirement for the drug development for
Guillain-Barre syndrome is expected to increase in the upcoming years."

Guillain-Barre syndrome: Segmentation analysis

This pipeline analysis report segments the Guillain-Barre syndrome
market based on therapies employed (monotherapy), RoA (oral,
intravenous, and subcutaneous), therapeutic modality (monoclonal
antibody, enzyme, peptide, and recombinant protein), targets (complement
component-5, cannabinoid receptor, complement component-1 q, and
complement component-6), MoA (complement component-5 inhibitor,
cannabinoid receptor agonists, complement component-1 q inhibitor, and
complement component-6 inhibitor, and immunosuppressants), geographical
segmentation (Japan) and recruitment status (completed). It provides an
in-depth analysis of the prominent factors influencing the market,
including drivers, opportunities, trends, and industry-specific
challenges.

Based on therapeutic modality, around 43% of the molecules that are
being investigated for the treatment of Guillain-Barre syndrome are
monoclonal antibody.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!